Search Results
Results found for "Domain Therapeutics"
- Trademark Policy | Dr. GPCR Ecosystem
restriction is prohibited by applicable law), and you agree not to register or attempt to register any domain For example, you may not use our marks: In domain names As app icons or featured in an app As the most
- GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem
From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general
- Fresh, Fresh, GPCR News â Feb 17 - 23, 2025 | Dr. GPCR Ecosystem
Terry Kenakinâs unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Australia GPCR Jobs NEW Open Postdoctoral position - Stanford University Structural Biologist - Confo Therapeutics Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic
- Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem
Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic micro environments could unlock new therapeutic strategies
- Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem
Whether a 20% reduction in beta-arrestin coupling matters therapeutically depends on the cell type, the drug response differences, and a largely unexplored opportunity in existing drug pipelines Antibody therapeutics Antibody therapeutics for GPCRs: the pipeline argument Biologics have a substantially higher success The combination of those two facts, Gilchrist argues, makes antibody-based GPCR therapeutics an underexplored The precedent of drugging a receptor without knowing what activates it naturally, and getting therapeutic
- Dr. Lauren M. Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Yao Lu (Jackie) | Dr. GPCR Ecosystem
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem
The therapeutic logic that follows is less about attacking the virus and more about rebalancing a GPCR-driven Dry-lab pharmacology and what becomes possible when wet-lab work stops GPCR density and tissue-specific therapeutic The review was accepted at Clinical Pharmacology and Therapeutics within weeks. If the virus disrupts one arm of this receptor-peptide system, the therapeutic question stops being "
- Dr. Aurélien Rizk | Dr. GPCR Ecosystem
the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.
- Terry Hébert | Dr. GPCR Ecosystem
Hebert's argument â that challenge trials depend on a reliable therapeutic the field did not yet have Challenge trials and the therapeutic floor â Why the ethics of accelerating vaccine trials depend on challenge trial â where volunteers receive placebo or active virus â is ethically unworkable without a therapeutic Terry HĂ©bert is a Professor within the Department of Pharmacology & Therapeutics at McGill University
- How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem
Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic | Dr. GPCR Ecosystem
The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to
- Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Your GPCR Order Has Arrived! â Feb 10 - 16, 2025 | Dr. GPCR Ecosystem
. đïž Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 â April biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic
- Celtarys Research | Dr. GPCR Ecosystem
Biology: The Role of Fluorescent Ligands in GPCR Research GPCRs are one of the most important families of therapeutic Celtarysâ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic
- Dr. Demet Araç | Dr. GPCR Ecosystem
Demet's research on the gain domain of adhesion GPCRs started during his postdoctoral studies and continued
- Brian Arey: Discovering Signaling Bias at the FSH Receptor | Dr. GPCR Ecosystem
He argues for a therapeutic strategy built around modulators that can be combined, rather than single agents designed to dominate a pathway. His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor | Dr. GPCR Ecosystem
the most clinically validated targets in metabolic disease - yet the signaling logic separating the therapeutic pharmacologists have not yet addressed actually shape signaling output at one of the field's most important therapeutic receptor Transducer coupling as the missing mechanistic layer in GLP-1 receptor pharmacology The expanding therapeutic modulate the functional output at this receptor, and whether that regulatory layer contributes to the therapeutic
- Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem
development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- Affiliate Policy | Dr. GPCR Ecosystem
GPCR name (including misspells and variations) as a sub-domain or sub-folder.
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
orphan GPCRs from âlockedâ, inaccessible receptors to well-characterized and understood âunlockedâ therapeutic
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Dr. Adriano Marchese | Dr. GPCR Ecosystem
The ultimate goal of Adrianoâs research is to target novel aspects of GPCR signaling for therapeutic
- Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Therapeutics She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Dr. Timo De Groof | Dr. GPCR Ecosystem
nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic



























